Share information about Vivelle-Dot® by emailing this Web site to a colleague.
After clicking the "Send" button below, your colleague will receive an email containing a link to this Web site.
The email addresses you furnish on this page will be used solely to send a link to the recipient. The addresses will not be retained or reused.
To learn more about our communications standards, please read our Privacy Policy.
Vivelle-Dot® uses an advanced technology to provide transdermal estrogen therapy (ET).
The skin metabolizes estradiol only to a small extent. In contrast, orally administered estradiol is rapidly metabolized by the liver to estrone and its conjugates, giving rise to higher circulating levels of estrone to estradiol. Therefore, transdermal administration produces therapeutic plasma levels of estradiol with lower circulating levels of estrone and estrone conjugates and requires smaller total doses than does oral therapy.
Vivelle-Dot delivers flexibility with 5 dosage strengths to meet individual needs.
*Vivelle-Dot 0.025 mg/day is indicated for the prevention of postmenopausal osteoporosis only.
For women interested in the source of estrogen in their therapy, the estrogen in Vivelle-Dot (estradiol) is chemically synthesized from a plant source. This does not mean Vivelle-Dot is safer or more effective than other hormone therapies.
See full Prescribing Information PDF.